• 100324+ Medical Conferences
  • 210 Specialties
  • 17857 Organizers
  • 121780 Speakers
  • 149 Countries
  • 3823 Cities
33441+
CME Conference Registrations Sold
Home  >  Online CME  >  Webcasts  >  Patient With Relapsed Large Cell Lymphoma: Reference Product or Biosimilar? Webinar by American Society of Hematology (ASH)
CME : 0.50

Patient With Relapsed Large Cell Lymphoma: Reference Product or Biosimilar? Webinar by American Society of Hematology (ASH)

Dec 04, 2017 - Dec 03, 2018
Length: NA
Specialties : Biotechnology   |   Haematology   |   Oncology
Conference Brochure

Conference Summary

Patient With Relapsed Large Cell Lymphoma: Reference Product or Biosimilar? Webinar is organized by American Society of Hematology (ASH) and will be held from Dec 04, 2017 - Dec 03, 2018.

The target audience for this medical event is Hematologists, hematologist/oncologists, oncologists, and others who are managing patients with neoplasms and need to stay updated on developments related to biosimilars. This CME Conference has been approved for a maximum of 0.5 Credit Hours.

Biosimilars: A New Era of Hematology/Oncology Management Considerations :
With the increasing entry of biosimilars into clinical practice, it is important to equip and prepare hematology/oncology clinicians with information that can provide a context for the appropriate use of biosimilars. This program looks to increase clinician awareness, knowledge, and confidence regarding the role of biosimilars in clinical care, which has the potential for a notably positive impact on patient access to biologic therapy, as well as the cost of care.

Part II: What Would You Do? :
Learners interpret the foundational information about biosimilars through the evaluation of three case-based scenarios.

Patient With Relapsed Large Cell Lymphoma: Reference Product or Biosimilar? :
In this webinar, Drs. Andrew Zelenetz and Gary Lyman review clinical trial data and discuss extrapolation as it relates to the potential use of a biosimilar in a patient with relapsed large cell lymphoma.

Learning Objectives :
• Define biosimilars, extrapolation, and interchangeability on the basis of FDA definitions and guidance
• Explain the basics of the FDA approval process and how it uses the “totality of evidence” to determine biosimilarity
• Explore data on safety and immunogenicity of originator biologics and biosimilars
• Examine relevant regulations concerning pharmacy substitution with biosimilars
• Apply the foundational knowledge on biosimilars into clinical situations relevant to hematology/oncology practice

Additional details will be posted as soon as they are available.

Speaking

Registration Desk

Contact No. 202-776-0544,
866-828-1231
Email
cme@hematology.org, bloodeditor@hematology.org

Conference Fee Details

Conference Fee : Free
Early Fee : NA
Early Fee Last date : NA

The rating has been saved.

Please Rate this Conference

 0.0
 0.0
 0.0
 0.0
 0.0

Reviews Given by People

No Reviews available. Be the first to write a review.
Close

Session Details

Session Topic Start Time End Time Location Description Speakers
Close

Workshop Details

Title Start Time End Time Workshop Fee
-->

Subscribe to our Newsletter

x

Subscribe to our newsletter and receive updates on medical conferences, board review courses and news